Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

09 Jan 2018

609.00

0.99%

Company Update

Statement Of Investor Complaints For The Quarter Ended 31St December 2017

BSE India

Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish hereunder the Statement of Investor Complaints for the Quarter ended December 31, 2017. S. No. Particulars No. of Investor Complaints (i) Pending at the beginning of the Quarter Nil (ii) Received during the Quarter 2 (iii) Disposed-off during the Quarter 2...

pdf

Laurus Labs Ltd.

09 Jan 2018

609.00

0.99%

Company Update

Statement Of Investor Complaints For The Quarter Ended 31St December 2017

BSE India

pdf

Laurus Labs Ltd.

04 Jan 2018

609.00

0.99%

Company Update

Shareholding for the Period Ended December 31, 2017

BSE India

Laurus Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here

Laurus Labs Ltd.

26 Dec 2017

609.00

0.99%

Company Update

Updates

BSE India

Sub: Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (PIT) Regulations 2015 With reference to the above subject, we have received the attached communication from one of our employees. The same is being sent herewith for your information and records.

pdf

Laurus Labs Ltd.

04 Dec 2017

609.00

0.99%

Company Update

Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the Analyst/ Institutional Investor meeting is scheduled(Edelweiss India Investor Conference) to be conducted on December 5, 2017 at Mumbai.

pdf

Laurus Labs Ltd.

30 Nov 2017

609.00

0.99%

Company Update

Press Release / Media Release

BSE India

Laurus Labs Ltd is pleased to announce that the Company has received its maiden Tentative Approval from United States Food and Drug Administration (U.S FDA) for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate Tablets 300mg is therapeutically equivalent to VIREAD Tablets 300mg of Gilead Science Ltd. (GILEAD)....

pdf

Laurus Labs Ltd.

24 Nov 2017

609.00

0.99%

Corp. Note

Resignation of Director

BSE India

Laurus Labs Limited is in receipt of resignation letter today from Mr. Rajesh Kumar Dugar, Nominee Director of the Company. The resignation is effective from the date of 23rd November 2017. A copy of the resignation letter is attached for your information and records.

pdf

Laurus Labs Ltd.

23 Nov 2017

609.00

0.99%

Earnings Call

Earnings Call Transcript

BSE India

Sub: Transcript of earnings call. Please refer to our letter dated 4th November 2017 wherein we have intimated the schedule of Investors/Analysts call on 10th November 2017. In this connection, please find attached transcription of conference call.

pdf

Laurus Labs Ltd.

14 Nov 2017

609.00

0.99%

Company Update

Press Release / Media Release

BSE India

Laurus Labs Limited has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its Unit 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in August 2017. A press release to this extent is also attached for your information and records.

pdf